Search academic texts

Information × Registration Number 2123U001923, Article popup.category Стаття Title popup.author Horcajada J.Salata R.Álvarez-Sala R.Mimi Nitu F.Lawrence L.Quintas M.Cheng C.Cammarata S. popup.publication 23-05-2023 popup.source_user Національний медичний університет імені О. О. Богомольця popup.source http://ir.librarynmu.com/handle/123456789/7699 popup.publisher Open Forum Infectious Diseases Description The clinical and economic burden of community-acquired bacterial pneumonia (CABP) is significant and is anticipated to increase as the population ages and pathogens become more resistant. Delafloxacin is a fluoroquinolone antibiotic approved in the United States for the treatment of adults with acute bacterial skin and skin structure infections. Delafloxacin’s shape and charge profile uniquely impact its spectrum of activity and side effect profile. This phase 3 study compared the efficacy and safety of delafloxacin with moxifloxacin for the treatment of CABP popup.nrat_date 2024-12-23 Close